Reboxetine
As of the edition of 20 October 2026, Reboxetine is a small molecule: marketed, first approved in 1998 (ES); acts on SLC6A2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Norebox
- First approved
- 1 October 1998 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 30, 9 stopped early
- Disease areas
- Mental health; Nervous system; Bones, joints and muscles; Chemically induced; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 6 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 14 | 5 | 3 | 6 |
| Phase 3 | 7 | 3 | 1 | 3 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 30 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 2000 to now |